|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | HOA LATAM | **Project Code** | PI5LSS017 |
| **Project Manager** | Debbie Greiner | **Clinical Program Manager** | Briana Betz |
| **Compliance** | ---------- | **Editor** | Christi Gray |

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**Items highlighted in GREEN are the Minimum Required Sections for creating an invite.**

1. **[Title---always italicized, no bold, no quotes]**

*Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion*

1. **[Congress-Specific Statement – not always necessary]**

*2015 Highlights of ASH® in Latin America*

1. **[Date/Time---Please do not use AM or PM for Ex-US projects]**

Thursday, April 23, 2015

4.15 pm–4.30 pm Registration

4.30 pm –6.00 pm Program

1. **[Location]**

Room TBD

Hotel Las Américas Resort, Spa, and Convention Center

Anillo Vial, Sector Cielo Mar

Cartagena de Indias, Colombia

1. **[Meeting Overview (or Statement of Need (if PIM is CME provider)]:**

**Symposia:**

We are pleased to invite you to our satellite symposium, Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion, to be held on April 23 at the 2015 Highlights of ASH® in Latin America meeting in Cartagena, Columbia.

1. **[Target Audience]**

This educational activity is designed for medical oncologists, radiation oncologists, surgeons, pathologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

1. **[Learning Objectives]**

Upon completion of this educational activity, participants should be able to:

* Identify the key pathologic features of HL and ALCL and strategies for improving diagnosis
* Describe the importance of risk-adapted therapy for newly diagnosed HL and emerging therapeutic options for initial therapy
* Employ best practices in the treatment of patients with relapsed/refractory HL, including optimal use of current and emerging treatment options
* Evaluate recent clinical trial data focused on the treatment of patients with relapsed/refractory ALCL and strategies for integrating these advances in patient care
* Describe best practices for the identification and management of treatment-related adverse events in patients with lymphoma to improve tolerability and quality of life

1. **[Faculty Listing---note bolding and lack of colons, alphabetical order]**

**Chair**

Otavio C.G. Baiocchi, MD, PhD

Federal University of São Paulo

São Paulo, Brazil

**Faculty**

Timothy Illidge, MD, PhD

University of Manchester

Manchester, United Kingdom

Miguel Piris, MD

Hospital Universitario Marqués de Valdecilla

Santander, Spain

Anas Younes, MD

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

1. **[Agenda]**

**Saturday, 28 February**

**Welcome and introduction**

#### Otavio C.G. Baiocchi, MD, PhD

**4.30 pm Keys to an accurate diagnosis of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL): The pathologist’s perspective**

Miguel Piris, MD

**4.40 pm Interactive clinical case #1: Initial Therapy for HL**

**4.45 pm Presentation**

#### Otavio C.G. Baiocchi, MD, PhD

**5.00 pm Questions from the audience**

**5.05 pm Interactive clinical case #2***:* **Relapsed/refractory HL**

**5.10 pm Presentation**

Anas Younes, MD

**5.25 pm Questions from the audience**

**5.30 pm Interactive clinical case #3***:* **Relapsed/refractory ALCL**

**5.35 pm Presentation**

Timothy Illidge, MD, PhD

**5.50 pm Questions from the audience**

**5.55 pm prIME Points™**

*Otavio C.G. Baiocchi, MD, PhD*

**Adjourn**

1. **Provider**

**Directly provided by prIME (\*prIME is the accredited - used for US and EX-US CME) or No CME:**

This activity is provided by prIME Oncology.

1. **[Continuing Education---choose one]**

**No CME**

Do not include a Continuing Education Statement.

\*\*All CME/CE verbiage should receive final approval from Regulatory/Compliance Manager

1. **Support Statement [ACCME—consult Cindy for proper verbiage and defer to BD for final approval of complete verbiage]**

This educational activity is supported by Takeda Oncology.

\*\*Only include logos on cover of print collateral if we include the accredited provider/joint providers logos as well.\*\* **[logos can only be included if they do not violate any of the rules and regulations below]**

**ACCME**

Effective June 1, 2014, any and all ACCME-accredited activities are prohibited from using any corporate logo as an acknowledgement of support.

Educational materials that are part of the CME activity cannot contain corporate logos of an ACCME defined commercial interest.

1. **[Registration/Fee Information]**

There is no fee for this activity and preregistration is not required; however, space is limited. Refreshments will be served.

1. **[Disclosures---can be in much smaller font if necessary]**

**No CME**

**Flyer**

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**Summary Book**

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Baiocchi has disclosed that he has ……………………. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Illidge has disclosed that he has ……………………. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Piris has disclosed that he has received consulting fees and fees for non-CME services from Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Younes has disclosed that he has ……………………. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
* Briana Betz, PhD (clinical content reviewer/planner) – no relevant financial relationships
* Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. **[Welcome/Chair Letter] used for invitation and/or email blast**

Welcome Letter

Dear Colleagues,

Welcome to Cartagena and the 2015 Highlights of ASH® in Latin America.

We are very pleased that you have chosen to attend this prIME Oncology satellite symposium, *Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion*. Through this educational activity, we aim to provide you with clinically relevant information on Hodgkin lymphoma and anaplastic large cell lymphoma that you can incorporate into your practice. We hope you find the unique format of our symposium informative and engaging.

We appreciate your attendance and welcome your active participation.

#### Otavio C.G. Baiocchi, MD, PhD

Federal University of São Paulo

São Paulo, Brazil

1. **[Back Page Copy] used for invitation and/or summary books**

EU Office

prIME Oncology

Schenkkade 50, Suite 16

2595 AR The Hague

the Netherlands

tel + 31.70.3067.190

US Office

prIME Oncology

Two Concourse Pkwy, Suite 270

Atlanta, Georgia 30328

United States

tel + 1.678.892.1340

www.prIMEoncology.org

About prIME Oncology

prIME Oncology is a global **pr**ofessional **I**ndependent **M**edical **E**ducation organization specializing in educational activities for physicians who treat patients with cancer. With the ultimate goal of improving patient outcomes, prIME Oncology provides evidence-based, state-of-the-art educational activities that assist oncology clinicians in making up-to-date and appropriate treatment decisions.

©2015 prIME Oncology

PI5LSS017

1. **[URL and Mobile App Name---give suggestions for URL name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

Insert URL here.

www.prIMEoncology.org/Lymphoma\_Cartagena2015

Program Book: www.prIMEoncology.org/Lymphoma\_Cartagena2015\_webcast

Page Title

Lymphoma | Cartagena

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): HL of ASH LATAM Symp

Meta Description  
**(**This should be roughly 150 characters in length. This is the short description that will appear beneath the activity title in search results, so it should be a compelling, keyword-rich description that will encourage the user to click)

Key Words/Key Phrases

Lymphoma, Non-Hodgkin Lymphoma, Hodgkin

1. **[Subject Line for Email Blast]**
2. Join Us in Cartagena: Examining Targeted Therapy in HL and NHL: A Case-Based Discussion
3. Register Now for a Symposium on Lymphoma – April 23 in Cartagena
4. **[Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Date/Time

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Disclosures

Providership (with logos)

Support (with logos\* - see Support, Section #13 for restrictions)

1. **[Registration Confirmation Copy]**

Insert Registration Confirmation Email copy here.

Thank you for registering for *Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion,* a satellite symposium at the 2015 Highlights of ASH® in Latin America.

Thursday, April 23, 2015

4.15 PM–4.30 PM REGISTRATION

4.30 PM–6.00 PM PROGRAM

Hotel Las Américas Resort, Spa, and Convention Center

Anillo Vial, Sector Cielo Mar

Cartagena de Indias, Colombia

Please do not hesitate to contact us should you require any further information.

Kind regards,

Debbie Greiner

prIME Oncology

678.892.1362

Email: [Debbie.Greiner@prIMEoncology.org](mailto:Debbie.Greiner@prIMEoncology.org)

1. **[Registration Confirmation Copy]**

You have cancelled the registration process. None of your information has been captured. To register, please return to the meeting home page.

If you experience difficulty registering, please contact the meeting organizer at info@prIMEoncology.org.

1. **[Other]**

Please add any additional copy needed but not listed above with a description of what it is and where it is needed.

**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** |  | **Project Code** |  |
| **Virtual Project Manager** | Choose an item. | **Clinical Program Manager** | Choose an item. |
| **Compliance** | Choose an item. | **Editor** | Choose an item. |

**Launch Date/Internal Launch Date:**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):  
  
Content Available by:

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast/PDS URL:**

[www.prIMEoncology.org/Lymphoma\_Cartagena2015\_Webcast](http://www.prIMEoncology.org/Lymphoma_Cartagena2015_Webcast)

www.prIMEoncology.org/Lymphoma\_Cartagena2015\_PDS

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

1. **[Meeting-Associated Downloadable Slides]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Downloadable Slides From Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion**

**ACTIVITY FEATURES**

[Icon] Downloadable Slides

[Insert screen shot]

**ACTIVITY OVERVIEW**

prIME Oncology invites you to view Downloadable Slides from the Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion Symposium held in Cartagena, Columbia.

\*\*\*May add a “in conjunction with \_\_\_\_\_\_\_” phrase if this is from a symposium at a congress.

**PROVIDER**

This activity is provided by prIME Oncology.

**[Tab—Insert Disease Topic]**

Discussant: **Name, Degree,** Institute, City, State, Country

Topic: Insert agenda topic

Learning Objective: Insert presentation-specific objective

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Name, Degree,** Institute, City, State, Country

Topic: Insert agenda topic

Learning Objective: Insert presentation-specific objective

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Name, Degree,** Institute, City, State, Country

Topic: Insert agenda topic

Learning Objective: Insert presentation-specific objective

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Discussant: **Name, Degree,** Institute, City, State, Country

Topic: Insert agenda topic

Learning Objective: Insert presentation-specific objective

[insert divider line]\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **[Meeting-Associated Webcast]---VERIFY with Clinical after the meeting to see what presentation are to be included**

**Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion**

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Icon] Podcast (if appropriate)

[Icon] CME-Certified (if appropriate)

**ACTIVITY OVERVIEW**

This Webcast contains **video and downloadable slides** from the symposium Examining Targeted Therapy in Hodgkin and Non-Hodgkin Lymphoma: A Case-Based Discussion, a prIME Oncology educational activity that was held on April 23, 2015, in Cartagena, Columbia.

**TOPICS**

[Insert Agenda topic]

[*Insert presenter name and degree(s)]*

[Insert Agenda topic]

[*Insert presenter name and degree(s)]*

[Insert Agenda topic]

[*Insert presenter name and degree(s)]*

**FACULTY**

**Chair**

Otavio C.G. Baiocchi, MD, PhD

Federal University of São Paulo

São Paulo, Brazil

**Faculty**

Timothy Illidge, MD, PhD

University of Manchester

Manchester, United Kingdom

Miguel Piris, MD

Hospital Universitario Marqués de Valdecilla

Santander, Spain

Anas Younes, MD

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

**TARGET AUDIENCE**

This educational activity is designed for medical oncologists, radiation oncologists, surgeons, pathologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

**LEARNING OBJECTIVES**

Upon completion of this educational activity, participants should be able to:

* Identify the key pathologic features of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) and strategies for improving diagnosis
* Describe the importance of risk-adapted therapy for newly diagnosed HL and emerging therapeutic options for initial therapy
* Employ best practices in the treatment of patients with relapsed/refractory HL, including optimal use of current and emerging treatment options
* Evaluate recent clinical trial data focused on the treatment of patients with relapsed/refractory ALCL and strategies for integrating these advances in patient care
* Describe best practices for the identification and management of treatment-related adverse events in patients with lymphoma to improve tolerability and quality of life

**METHOD OF PARTICIPATION [if applicable]**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with XX% or higher.

**DISCLOSURES [if applicable]**

Insert disclosure info from the live meeting.

**PROVIDER**

This Webcast is provided by prIME Oncology.

**SUPPORTER**

This educational activity is supported by Takeda Oncology.

**ACTIVITY DATE**

May XX 2015

May XX 2016

**MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app.

1. **Web Activity Page Titles**

Landing Page Title:  
Activity Page Title:

1. **Meta Description  
   (One description for each page (including landing pages and all activity pages.** This should be roughly 150 characters in length. This is the short description that will appear beneath the activity title in search results, so it should be a compelling, keyword-rich description that will encourage the user to click)
2. **Key Words and Key Phrases  
   (Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:***squamous cell nsclc  
   nsclc mutations  
   egfr mutations in nsclc  
   lung cancer nsclc  
   etc*